三诺生物
(300298)
| 流通市值：74.14亿 | | | 总市值：92.16亿 |
| 流通股本：4.48亿 | | | 总股本：5.57亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,537,036,279.21 | 1,239,411,700.81 | 4,659,335,913.5 | 3,453,271,477.26 |
| 营业收入 | 2,537,036,279.21 | 1,239,411,700.81 | 4,659,335,913.5 | 3,453,271,477.26 |
| 二、营业总成本 | 2,281,588,826.25 | 1,113,224,377.19 | 4,459,321,309.32 | 3,338,133,962.97 |
| 营业成本 | 1,187,526,252.94 | 588,608,625.74 | 2,388,466,450.2 | 1,764,409,923.1 |
| 税金及附加 | 23,874,745.87 | 12,363,009.02 | 45,934,051.4 | 33,673,942.46 |
| 销售费用 | 705,697,194.6 | 325,275,003.29 | 1,258,301,474.99 | 926,492,495.02 |
| 管理费用 | 219,498,884.31 | 115,186,368.08 | 456,821,095.98 | 354,668,196.17 |
| 研发费用 | 123,213,911.44 | 61,339,099.59 | 274,631,109.46 | 224,193,796.26 |
| 财务费用 | 21,777,837.09 | 10,452,271.47 | 35,167,127.29 | 34,695,609.96 |
| 其中:利息费用 | 18,761,901.38 | 9,150,988.18 | 38,881,795.3 | 29,333,003.23 |
| 其中:利息收入 | 7,239,325.07 | 3,849,772.16 | 21,556,449.1 | 17,483,947.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,440,428.08 | 332,347.73 | 1,345,429.99 | 558,193.25 |
| 加:投资收益 | 200,291.29 | 366,566.97 | 1,401,010.78 | 1,308,350.85 |
| 资产处置收益 | 292,657.07 | -58,150.37 | -1,143,532.66 | -603,543.7 |
| 资产减值损失(新) | -4,896,616.53 | -3,294,847.49 | -184,317,259.7 | -1,112,227.84 |
| 信用减值损失(新) | -2,265,577.27 | -17,412,423.62 | -10,757,730.24 | 10,955,465.21 |
| 其他收益 | 14,904,072.14 | 11,506,797.28 | 57,464,502.98 | 50,372,354.23 |
| 四、营业利润 | 265,122,707.74 | 117,627,614.12 | 64,007,025.33 | 176,616,106.29 |
| 加:营业外收入 | 4,322,088.12 | 3,870,393.42 | 15,485,531.49 | 14,892,090.65 |
| 减:营业外支出 | 1,239,717.32 | 1,101,540.62 | 5,438,519.75 | 740,973.1 |
| 五、利润总额 | 268,205,078.54 | 120,396,466.92 | 74,054,037.07 | 190,767,223.84 |
| 减:所得税费用 | 41,524,473.41 | 17,405,072.68 | 51,977,363.02 | 38,023,274.68 |
| 六、净利润 | 226,680,605.13 | 102,991,394.24 | 22,076,674.05 | 152,743,949.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 226,680,605.13 | 102,991,394.24 | 22,076,674.05 | 152,743,949.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 221,337,341.6 | 97,685,838.82 | 92,648,858.69 | 211,003,372.35 |
| 少数股东损益 | 5,343,263.53 | 5,305,555.42 | -70,572,184.64 | -58,259,423.19 |
| 扣除非经常损益后的净利润 | 210,299,160.14 | 90,881,721.44 | 59,020,547.98 | 180,384,969.71 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 0.18 | 0.17 | 0.38 |
| (二)稀释每股收益 | 0.41 | 0.18 | 0.17 | 0.38 |
| 八、其他综合收益 | -52,000,501.43 | -27,511,297.91 | -34,957,876.86 | -4,351,539.6 |
| 归属于母公司股东的其他综合收益 | -35,621,131.15 | -18,527,344.57 | -26,988,265.98 | -5,958,810.65 |
| 九、综合收益总额 | 174,680,103.7 | 75,480,096.33 | -12,881,202.81 | 148,392,409.56 |
| 归属于母公司股东的综合收益总额 | 185,716,210.45 | 79,158,494.25 | 65,660,592.71 | 205,044,561.7 |
| 归属于少数股东的综合收益总额 | -11,036,106.75 | -3,678,397.92 | -78,541,795.52 | -56,652,152.14 |
| 公告日期 | 2026-08-04 | 2026-04-28 | 2026-04-28 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |